Harpoon Therapeutics, Inc

122 articles with Harpoon Therapeutics, Inc

• Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

  4/7/2022

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference.

• Harpoon Therapeutics Announces Leadership Change

  4/7/2022

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, 2022.

• 

  Harpoon to Discontinue Once Promising Treatment for Prostate Cancer

  3/11/2022

  Harpoon Therapeutics, Inc. has unfortunately announced that it will move to discontinue one of its promising T cell engager biologics, HPN424.

• Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/10/2022

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

• Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

  3/7/2022

  Harpoon Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a delta like ligand 3- (DLL3) targeting TriTAC ® , for the treatment of small cell lung cancer (SCLC).

• Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

  3/2/2022

  Harpoon Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC ® .

• Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

  1/11/2022

  Harpoon Therapeutics, Inc. today provided a pipeline milestone update on its TriTAC development programs.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms   

  12/13/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), today provided a pipeline update on its programs, including the interim data presented from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma (R/R MM) at the 63rd American Society for Hematology (ASH) Annual Meeting and Exposition.

• Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

  12/11/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma at the 63rd American Society for Hematology Annual Meeting and Exposition.

• Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

  12/7/2021

  Harpoon Therapeutics, Inc. today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline programs.

• Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

  11/12/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer in Washington, D.C.

• Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/10/2021

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences - Nov 09, 2021

  11/9/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that management will participate in two upcoming virtual investor conferences.

• Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

  11/4/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology Annual Meeting and Exposition.

• Harpoon Therapeutics Announces Change to Management Team and Board of Directors

  10/26/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Julie Eastland has been named President and Chief Executive Officer, effective November 8, 2021.

• Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

  10/5/2021

  Harpoon Therapeutics, Inc. today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

• Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences in September 2021

  9/2/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual investor conferences.

• Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences - Aug 03, 2021

  8/3/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences